ETV4 and endocervical adenocarcinoma: High expression of ETV4 predicted poorer progression-free interval for GBMLGG, ACC, MESO, PCPG, LGG, and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and better progression-free interval for ovarian serous cystadenocarcinoma (Figures 2C, 3C).